Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Can Do Ramadan
2015-002104-91Phase 4Completed
- Sponsor
- University of Leicester
- Start
- Feb 2016
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of canagliflozin, gliclazide, glimepiride, glibenclamide, glipizide and 2 more in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Leicester. Primary endpoint: Primary composite endpoint. Started Feb 2016; status: completed.
02
Drugs
canagliflozingliclazideglimepirideglibenclamideglipizide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-002104-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002104-91.